Biofund
VC Fund
Siena, Italy
Biofund is a VC fund in Siena focused on Genetics and Health Care. BIOFUND SpA, established by Fondazione Monte dei Paschi, Bank Monte dei Paschi , Finanziaria Senese di Sviluppo e Fidi Toscana, provides the initial seed capital for companies located in the incubator of Toscana Life Sciences in Siena.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Biofund invests in
Stages Biofund invests in
Countries Biofund invests in
Investment Focus
Industry
- Genetics 3 (50%)
- Health Care 3 (50%)
- Health Diagnostics 3 (50%)
- Medical 2 (33%)
- Life Science 2 (33%)
Stage
- Funding Round 3 (50%)
- Pre-Seed 2 (33%)
- Seed 1 (17%)
Country
- Italy 2 (33%)
- Canada 2 (33%)
- Denmark 1 (17%)
- Russian Federation 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EXE Engineering
|
EXE-Engineering for Environment. Miglioriamo i sistemi produttivi per rendere meno impattanti le attività umane | Pre-Seed / May 01, 2020 | |
DX Medical Solutions
|
DX Medical Solutions is a medical technology startup that uses machine learning and artificial intelligence to create efficient health monitoring and analysis systems. With a focus on providing personalized care, the company's product Diagnostix, collects data from a variety of sources and processes it through advanced algorithms to gain deepinsights into patient health. DX Medical Solutions contributes to better overall health outcomes while reducing the burden on the healthcare system. | $500K / Pre-Seed / Nov 01, 2019 | |
RTM Diagnostika
|
Diagnostic microwave radio RTM-01-RESThe temperature and rate of growth of malignant tumorsCancer is the terrible disease of breast. That is why the full range of diagnostic measures in mammalogy aimed primarily at identifying it. It is known that the malignant tumor has a higher temperature compared with surrounding tissues. These data werefirst obtained Guture M. French scientist, who, after more than 550 invasive measurements demonstrated that malignancy is determined by its temperature is doubling time. Therefore, the most dangerous, rapidly growing tumors have a very high temperature. It is also known that thermal changes, usually preceded by structural changes. In particular, the thermal changes of the mammary glands come not a moment when the cancer reaches the required size, but much earlier. Studies have shown that even at the stage preceding the malignant growth, namely, when the cells have the expressed proliferation, accompanied by atypical changes, increases the density of microcapillary network, and as a consequence there is a local increase in temperature. Indisputable is the fact that patients with these changes have a high risk of malignancy. Many authors classify this condition as precancerous.The internal temperature - measure of angiogenesisIn 2003, Japanese scientists have shown that the temperature in the cancerous region determined by the density microcapillary network (microvessel density (MVD) [8]. This is the main parameter that characterizes angiogenesis. The density of the microcapillary network when proliferation atypia several times greater than the rate for normal tissues and characterizes the risk of malignancy. in addition, the microcapillary network density refers to the probability of transformation from noninvasive to invasive cancer, the probability of metastasis and tumor growth rate. Therefore, the internal temperature, as a measure of angiogenesis, provides important information about the development of cancer. | $166K / Seed / Jun 22, 2016 | |
Genizon BioSciences
|
Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. | $12M / Mar 29, 2006 | |
Exiqon
|
Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences. | $20M / Jun 03, 2005 | |
Galileo Genomics
|
Galileo genomics is a Montreal-based private genetics company that conducts research in Quebecers of French descent using cutting-edge technologies, to identify genes that cause disease, thus providing validated targets for creation of innovative and more effective therapies and diagnostics. The Quebec founder population is the largest suchpopulation worldwide, which facilitates rapid patient recruiting. Because of the relatively late founding of the population in the 17th century, the relatively small number of founders, rapid early population growth, minimal intermarriage with other groups, and loss of some family lines while others expanded dramatically, the population is among the most homogeneous and has among the highest genetic sharing of all major founder populations. | $9M / Jan 08, 2004 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Biofund invest in?
Biofund invests primarily in Genetics, Health Care and Health Diagnostics startups, most often at Funding Round and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Biofund last invest?
The most recent investment recorded for Biofund closed in May 2020. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
